Dynavax Melanoma Trial

CONDITION

Cancer

GENDER

Both males and females

AGE GROUP

From 18

to 70 years

STATUS

Completed

This trial is designed to evaluate the safety, tolerability, and preliminary efficacy of intra-tumour injections of SD-101 in combination with intravenous Keytruda (pembrolizumab) in patients with metastatic melanoma.

Patients can have progressed on prior treatment with Keytruda or other anti-PD1 therapy or can have not yet received Keytruda/other anti-PD1 therapy.  More information can be found here. 

 

CONTACT DETAILS

Clinical Trial Site: Affinity Murdoch
Phone Number: (08) 9242 7640 Email: info@affinityresearch.com.au Location: 95 Monash Avenue, Nedlands Western Australia, Australia
  • Hidden

Approved By: Bellberry Limited              

Clinical Trial Registry Link: Click Here